• Publications
  • Influence
Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.
A registry of suspected cases of cancer-associated hemolytic-uremic syndrome (C-HUS) was established in May 1984. Records of 85 patients from the registry, all with history of cancer, hematocrit lessExpand
  • 265
  • 11
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.
Sixty-two patients with advanced measurable gastric cancer were treated with a combination chemotherapy program of 5-fluorouracil, doxorubicin, and mitomycin (FAM). Forty-two percent of patientsExpand
  • 318
  • 7
Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.
The antitumor activity of 5-fluoruoracil (5-FU) for two murine colonie adenocarcinomas was correlated with the concentration and the clearance of the active antimetabolite, 5-fluorodeoxyuridylateExpand
  • 54
  • 6
Twenty-seven patients with advanced diffuse histiocytic lymphoma (reticulum-cell sarcoma) were treated with combination chemotherapy utilising nitrogen mustard (or cyclophosphamide), procarbazine,Expand
  • 459
  • 5
Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders.
Substantial evidence has accumulated to indicate not only that mycosis fungoides and the Sézary syndrome are closely related malignancies, but to suggest that they are part of a larger spectrum ofExpand
  • 599
  • 5
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.
Fifteen of 52 patients (29%) with diffuse histiocytic and undifferentiated pleomorphic lymphoma developed central nervous system (CNS) complications, primarily leptomeningeal lymphoma. LumbarExpand
  • 226
  • 5
  • PDF
Gastrointestinal toxicity of chemotherapeutic agents.
Chemotherapy-induced toxicities commonly occur in sites within the gastrointestinal (GI) tract and account for dose-limiting effects. These toxicities are major contributing factors to doseExpand
  • 145
  • 5
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma
This controlled trial compared the survival of 90 patients with locally advanced gastric carcinoma treated with either chemotherapy alone (5‐FU and methyl‐CCNU) or external radiotherapy of 5000 radExpand
  • 170
  • 4
The use of drugs in combination for the treatment of cancer: rationale and results.
INTEREST in the use of drugs in combination tor the treatment of cancer is not a new phenomenon. It stems from the inability to obtain entirely satisfactory results when available agents are given ...
  • 183
  • 3
5‐fluorouracil, adriamycin, and mitomycin‐c (fam) combination chemotherapy in the treatment of advanced gastric cancer
Thirty‐six patients with advanced measurable gastric cancer were treated with a new combination chemotherapy program consisting of 5‐fluorouracil, Adriamycin and mitomycin‐C (FAM). Fifty percent ofExpand
  • 114
  • 3